Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). June 25, 2026 press release furnished under Regulation FD, making the disclosure publicly available to all investors.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- June 25, 2026 press release furnished under Regulation FD, making the disclosure publicly available to all investors
- Exhibit 99.1 contains the substantive company update and is the key document for assessing market impact
Item 8.01 · Other Events
- Forward-looking statements subject to standard SEC disclaimer and uncertainty
- Kymera disclaims obligation to update projections after disclosure date
- Investors should rely on subsequent SEC filings for updated company outlook
Item EX-99.1 · Exhibit EX-99.1
- BROADEN2 Phase 2b enrollment completed nearly six months early, accelerating KT-621 atopic dermatitis topline data to year-end 2026
- Phase 3 atopic dermatitis trials targeted for mid-2027, subject to regulatory discussions
- Trial evaluates three KT-621 doses in approximately 200 patients ages 12–75 over 16 weeks
- BREADTH Phase 2b eosinophilic asthma trial remains ongoing, with data expected in late 2027
- Earlier data could reduce development uncertainty, but Phase 2b efficacy and safety remain key valuation catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.